Searle
Executive Summary
Met with FDA on Aug. 26 to discuss differences between its Calan SR sustained-release verapamil product and Ivax' recently-approved generic version. At the meeting, FDA reaffirmed its position that the Ivax verapamil product is bioequivalent to Searle's Calan SR and will receive an "AB" rating. Searle petitioned the agency on Aug. 5 to stay the granting of an "AB" therapeutic equivalence rating for the Ivax product on the grounds that Ivax had not conducted "necessary" stereochemistry and chiral studies ("The Pink Sheet" Aug. 10, p. 6). The company and FDA have agreed that the issue should be reviewed by FDA's Generic Drugs Advisory Committee; however, the next meeting has not yet been scheduled.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth